These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11810555)

  • 21. Activity of grepafloxacin and other fluoroquinones and newer macrolides against recent clinical isolates of Chlamydia pneumoniae.
    Roblin PM; Kutlin A; Reznik T; Hammerschlag MR
    Int J Antimicrob Agents; 1999 Jul; 12(2):181-4. PubMed ID: 10418764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae.
    Takahata M; Shimakura M; Hori R; Kizawa K; Todo Y; Minami S; Watanabe Y; Narita H
    Antimicrob Agents Chemother; 2001 Jan; 45(1):312-5. PubMed ID: 11120986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas.
    Waites KB; Crabb DM; Duffy LB
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3973-5. PubMed ID: 14638513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients.
    Ishiguro N; Koseki N; Kaiho M; Ariga T; Kikuta H; Togashi T; Oba K; Morita K; Nagano N; Nakanishi M; Hara K; Hazama K; Watanabe T; Yamanaka T; Sasaki S; Furuyama H; Shibata M; Shida S; Ishizaka A; Tabata Y; Aoyagi H; Naito H; Yoshioka M; Horino A; Kenri T;
    PLoS One; 2017; 12(3):e0173635. PubMed ID: 28288170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In-vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum to clinafloxacin, PD 131628, ciprofloxacin and comparator drugs.
    Cohen MA; Huband MD
    J Antimicrob Chemother; 1997 Aug; 40(2):308-9. PubMed ID: 9302005
    [No Abstract]   [Full Text] [Related]  

  • 26. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe.
    Critchley IA; Jones ME; Heinze PD; Hubbard D; Engler HD; Evangelista AT; Thornsberry C; Karlowsky JA; Sahm DF
    Clin Microbiol Infect; 2002 Apr; 8(4):214-21. PubMed ID: 12047413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of grepafloxacin and 25 other antimicrobial agents against Streptococcus pneumoniae: correlation with penicillin resistance.
    Thornsberry C; Ogilvie PT; Holley HP; Sahm DF
    Clin Ther; 1998; 20(6):1179-90. PubMed ID: 9916611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bactericidal activity of moxifloxacin compared to grepafloxacin and clarithromycin against Streptococcus pneumoniae and Streptococcus pyogenes investigated using an in vitro pharmacodynamic model.
    Esposito S; Noviello S; Ianniello F
    J Chemother; 2000 Dec; 12(6):475-81. PubMed ID: 11154028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative susceptibility of Mycoplasma pneumoniae to erythromycin, ciprofloxacin, and lomefloxacin.
    Cassell GH; Waites KB; Pate MS; Canupp KC; Duffy LB
    Diagn Microbiol Infect Dis; 1989; 12(5):433-5. PubMed ID: 2515025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of tetracyclines, macrolides, quinolones, clindamycin and metronidazole against periodontopathic bacteria.
    Miyake Y; Tsuruda K; Okuda K; Widowati ; Iwamoto Y; Suginaka H
    J Periodontal Res; 1995 Jul; 30(4):290-3. PubMed ID: 7562327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp.
    Duffy LB; Crabb D; Searcey K; Kempf MC
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():29-33. PubMed ID: 10824029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro activities of quinupristin-dalfopristin and the streptogramin RPR 106972 against Mycoplasma pneumoniae.
    Izumikawa K; Hirakata Y; Yamaguchi T; Yoshida R; Tanaka H; Takemura H; Maesaki S; Tomono K; Kaku M; Izumikawa KI; Kamihira S; Kohno S
    Antimicrob Agents Chemother; 1998 Mar; 42(3):698-9. PubMed ID: 9517955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
    Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
    Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial activity and spectrum of sparfloxacin tested against erythromycin-resistant Streptococcus pneumoniae isolates.
    Barrett MS; Jones RN
    Diagn Microbiol Infect Dis; 1996 Feb; 24(2):113-6. PubMed ID: 9147907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of macrolide resistance in Mycoplasma pneumoniae isolated from children in Shanghai, China.
    Liu Y; Ye X; Zhang H; Xu X; Li W; Zhu D; Wang M
    Diagn Microbiol Infect Dis; 2010 Aug; 67(4):355-8. PubMed ID: 20638604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [In vitro activity of sparfloxacin against mycoplasmas].
    Renaudin H; Bebear C
    Pathol Biol (Paris); 1992 May; 40(5):450-4. PubMed ID: 1323094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experimental and clinical studies of sparfloxacin in Mycoplasma pneumoniae infection.
    Kaku M; Ishida K; Kohno S; Koga H; Hara K; Usui T
    Drugs; 1995; 49 Suppl 2():412-3. PubMed ID: 8549381
    [No Abstract]   [Full Text] [Related]  

  • 38. In vitro evaluation of activities of azithromycin, clarithromycin and sparfloxacin against Chlamydia trachomatis.
    Lefèvre JC; Escaffre MC; Courdil M; Lareng MB
    Pathol Biol (Paris); 1993 Apr; 41(4):313-5. PubMed ID: 8233628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro susceptibility of Chlamydia pecorum to macrolides, tetracyclines, quinolones and beta-lactam.
    Pudjiatmoko ; Fukushi H; Ochiai Y; Yamaguchi T; Hirai K
    Microbiol Immunol; 1998; 42(1):61-3. PubMed ID: 9525782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.
    Miyashita N; Niki Y; Kishimoto T; Nakajima M; Matsushima T
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1331-4. PubMed ID: 9174194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.